San Francisco, Calif. – April 23, 2014 – Cooley LLP announced today that it advised the underwriters on TriVascular Technologies, Inc.'s initial public offering. TriVascular is a medical device company that develops and commercializes innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. It now trades on the NASDAQ Global Stock Market under the symbol "TRIV."

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated acted as co-managers.

The Cooley corporate and securities team advising the underwriters was led by partners Charlie Kim, Drew Williamson and David Peinsipp, and included associates Jonie Kondracki, Veer Bhavnagri, Robert E. Jones and Joe Sexton. Critical support for the offering was provided by partner Scott Talbot and associates Scott Weston and Ariana Hiscott (intellectual property); partners Natasha Leskovsek and Wendy Goldstein, special counsel Phil Mitchell and associate Jennifer Shanley (regulatory); partners Danish Hamid and Kevin King (FCPA and OFAC); partner Renee Deming and associate Sarah Dale (compensation & benefits); and partner Susan Philpot (tax).
 
Year-to-date in 2014, Cooley has advised on 47 completed public offerings, including 24 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.